GlassScriptPhysician profile
Christy Lent
NPI 1265146708
$2,956.85
in general payments reported to CMS, 2019-2025
22 companies · $1,688 in 2025
The $1,688 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41.80 · 2023: $433 · 2024: $795 · 2025: $1,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,915.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $1,154.90 | 2025 | Rapiblyk |
| Merck Sharp & Dohme LLC | $327.21 | 2023-2025 | Verquvo, Capvaxive |
| Cvrx, INC. | $206.78 | 2023-2025 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.00 | 2023-2025 | Jardiance |
| Amgen INC. | $151.24 | 2024 | Repatha |
| Pfizer INC. | $143.62 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $103.43 | 2023-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $95.85 | 2024 | Camzyos |
| Boston Scientific Corporation | $73.19 | 2025 | Watchman Flx, General - Ep |
| Atricure, INC. | $71.99 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $71.23 | 2024-2025 | Farxiga |
| Kestra Medical Technology Services, INC. | $69.46 | 2024-2025 | Assure Wcd |
| Novo Nordisk INC | $55.41 | 2022-2023 | Wegovy |
| Novartis Pharmaceuticals Corporation | $53.96 | 2024-2025 | |
| Esperion Therapeutics, INC. | $40.87 | 2024-2025 | Nexletol |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $35.29 | 2024 | Linq II, Closurefast |
| Bayer Healthcare Pharmaceuticals INC. | $32.58 | 2024 | |
| Janssen Pharmaceuticals, INC | $32.48 | 2023-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $25.25 | 2025 | Uptravi, Opsynvi |
| Sanofi-Aventis U.S. LLC | $21.90 | 2023 | |
| Alnylam Pharmaceuticals INC. | $21.05 | 2025 | Amvuttra |
| Regeneron Healthcare Solutions, INC. | $16.16 | 2023 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christy Lent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.